ProCE Banner Activity

The CLL Treatment Revolution

Clinical Thought
Expert insight on treatment selection for patients with relapsed chronic lymphocytic leukemia.

Released: May 26, 2015

Expiration: May 24, 2016

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Novartis Oncology

Faculty Disclosure

Primary Author

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees and funds for research support from Acerta, Celgene, Genentech, Gilead Sciences, Pharmacyclics, Seattle Genetics, and TG Therapeutics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees and funds for research support from Acerta, Celgene, Genentech, Gilead Sciences, Pharmacyclics, Seattle Genetics, and TG Therapeutics.